Harvard Medical School - Partners Healthcare Center for Genetics and Genomics
Partners Healthcare Harvard Medical School Partners Healthcare Center for Genetics and Genomics
Harvard Medical School

Portal Login

About HPCGG
Scientific Leadership
Center Faculty
HPCGG Staff
Lab for Molecular Medicine
Genetic Tests
Genetics Glossary
Clinical Services
Services for Researchers
DNA Sequencing
MicroArrays
Genotyping
Proteomics
Biosample Services
Consultation
Gene Modification Lab
Bioinformatics
Educational Programs
Information Technology
Collaborations
Giving Opportunities
Job Opportunities
Sitemap
HPCGG Home
 

Search www.hpcgg.org
Search WWW

 
Scientific Leadership Kucherlapati
Scientific Leadership Advisory Council Center Faculty

Raju Kucherlapati  

Dr. Raju Kucherlapati

Scientific Director of Harvard Partners Center
for Genetics and Genomics
Paul C. Cabot Professor of Genetics, Harvard Medical School

Brigham and Women's Hospital
New Research Building, Room 250
77 Avenue Louis Pasteur
Boston, MA 02115

Tel: (617) 525-4445 | (617) 768-8508
Fax: (617) 525-4440
Email: rkucherlapati@partners.org


Our laboratory has four major areas of interest.

Mammalian Genomics Our laboratory has been involved in the mapping and sequencing of the human/ and mouse genomes using yeast artificial chromosomes and later, bacterial artificial chromosomes. We made a detailed physical map of human chromosome 12. In collaboration with the Genome Center at Baylor College of Medicine, we have finished the sequence of this chromosome. We were involved in mapping and cloning several human disease genes on this chromosome. They include, Noonan syndrome, Darier disease, Cornea plana and Holt-Oram syndrome. We have also contributed to the draft sequence of the mouse genome. We use the mapping and sequencing expertise to clone new human disease genes.

Molecular Etiology of Velo-Cardio-Facial/ DiGeorge Syndrome (VCFS/DGS) VCFS/DGS is a relatively common human syndrome. Children with VCFS/DGS present with a spectrum of phenotypes including cardio-vascular defects, immunological abnormalities, muscle weakness, hypernasal speech and learning disabilities. As they grow older, a large portion of them also develop psychiatric illness. The disorder results from haploinsufficiency of a 3 Mb region on human chromosome 22q11. We constructed detailed maps of this region and identified genes encoded by the DNA in 22q11. Using genetic engineering technologies, we made mice that carry a deletion in a region of the genome that corresponds to human 22q11. These mice exhibit some of phenotypes observed in VCFS/DGS patients. Using BAC complementation, we narrowed the critical region and identified a candidate gene, Tbx1. When Tbx1 is mutated, the mice develop vascular defects similar to those seen in human VCFS/DGS patients. We are now interested in understanding how haploinsufficiency of Tbx1 causes the major phenotypes of VCFS/DGS.

Mouse Models for Human Cancer We have a long-standing program to understand the role of genes involved in human colorectal cancer. Towards this goal, we used genetic engineering technologies to make mice with mutations in each of a large set of genes suspected to be involved in the initiation and progression of gastrointestinal cancer. These genes include, APC, MCC, N-RAS, SMAD2, SMAD4, MSH2, MSH3, MSH4, MSH5, MSH6, MLH1, FEN1 and ARVCF. Mice with mutations in Apc, Msh2, Msh6 and Mlh1 show a cancer predisposition phenotype. Mice with mutations in Smad4, Msh3, Fen1 and Arvcf do not develop tumors but mutations in these genes increase tumor susceptibility in Apc mutant mice. Mice with mutations in MlH1, Msh4 and Msh5 are sterile. The sterility is caused by meiotic arrest. We are interested in examining the roles of these and other genes in cancer initiation and progression.

Noonan Syndrome (NS). Noonan syndrome (NS) is an autosomal dominant disorder affecting an estimated 1/100 (mildly affected) to 1/1000-2,500 (severely affected) people. There is considerable heterogeneity in expression. Affected patients have typical facial features and may have congenital heart disease, motor delay, learning problems or mental retardation, hearing loss, visual problems, chest deformity, scoliosis, undescended testes, pubertal delay, short stature, or a bleeding disorder (Mendez 1985, Noonan 1994).

Early studies found that between 45% and 50% of individuals with Noonan syndrome have identifiable mutations in the PTPN11 gene (Tartaglia 2001, Tartaglia 2002). Preliminary genotype phenotype correlations demonstrate that familial cases of NS and patients with pulmonary valve stenosis are more likely to have a PTPN11 mutation (Tartaglia 2002).

The purpose of our research is to identify how many patients with Noonan syndrome, patients with a Noonan-like syndrome, or patients with isolated pulmonary valve disease or hypertrophic cardiomyopathy have a mutation in the PTPN11 gene. The study involves collecting DNA samples for PTPN11 testing, completing physical exams, reviewing past medical histories and compiling family histories of all participants. The test results and medical information obtained from participants in the study will be used to make phenotype genotype correlations in the mutation positive patients. These correlations will hopefully improve diagnosis, treatment and counseling.

References NCBI PubMed search of "R. Kucherlapati"

Montgomery, K.T., Lee, E., Miller, A., Lau, S., Shim, C., Decker, J., Chiu, D., Emerling, S., Sekhon, M., Kim, R., Lenz, J., Han, J., Ioshikhes, I., Renault, B., Marondel, I., Yoon, S.-J. K., Song, K., Murty, V.V.V.S., Scherer, S., Yonescu, R., Kirsch, I.R., Ried, T., McPherson, J., Gibbs, R. and Kucherlapati, R. (2001) A high-resolution map of human chromosome 12. Nature 409: 945-946.

Merscher, S., Funke, B., Epstein, J.A., Heyer, J., Puech, A., Lu, M.M., Xavier, R.J., Demay, M.B., Russell, R.G., Factor, S., Tokooya, K., St. Jore, B., Lopez, M., Pandita, R.K., Lia, M., Carrion, D., Schorle, H., Kobler, J.B., Scambler, P., Wynshaw-Boris, A., Skoultchi, A.I., Morrow, B.E. and Kucherlapati, R. (2001) TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell 104: 619-629.

Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415:526-30.

Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L. (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295:1726-9.

 

 


Please send your comments or questions regarding this website to web master.